Tempest Therapeutics
TPST
36 hedge funds and large institutions have $73.9M invested in Tempest Therapeutics in 2013 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
3% more funds holding
Funds holding: 35 → 36 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $75.7M → $73.9M (-$1.74M)
50% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TS
Third Security
Radford,
Virginia
|
+$2.55M |
| 2 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
+$905K |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$548K |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$329K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$192K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$1.15M |
| 2 |
BCM
BBT Capital Management
Fort Worth,
Texas
|
-$219K |
| 3 |
Jane Street
New York
|
-$195K |
| 4 |
AP
Appleton Partners
Boston,
Massachusetts
|
-$144K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$110K |
TPST Hedge Fund Activity: Q4 2013 in Review
36 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q4 2013, worth a combined $73.9M — down 2.3% from $75.7M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TPST positions and 4 closed out — a net gain of 1 holder — while 5 added to existing stakes and 10 trimmed.
The largest buyer was Third Security, opening a new position worth an estimated $2.55M. The largest seller was JP Morgan Chase, cutting an estimated $1.15M.
- 36 institutional investors held Tempest Therapeutics (TPST) as of Q4 2013, up from 35 in Q3 2013.
- Funds reported $73.9M of Tempest Therapeutics stock for Q4 2013, down 2.3% quarter-over-quarter.
- 5 funds opened new Tempest Therapeutics positions in Q4 2013 and 4 closed out, a net change of +1 holder.
- The largest Tempest Therapeutics buyer in Q4 2013 was Third Security, an estimated $2.55M added.
- The largest Tempest Therapeutics seller in Q4 2013 was JP Morgan Chase, an estimated $1.15M sold.
Based on aggregated 13F filings for Q4 2013.